Pharmaceuticals

Tilray Brands

Tilray Brands Launches Non-Alcoholic Drink Clean Slate and Low-Sugar Cocktail

Potential Rescheduling of Marijuana by Trump Administration Leads to Tilray Brands Stock Surge

Tilray Brands Reiterates Leadership in Medical Cannabis

Tilray Acquires Lyphe to Boost UK Healthcare Platform

Tilray Brands released FY2026 9-month earnings on April 1 Pre-Market (EST), actual revenue USD 633.74 M, actual EPS USD -0.653

Tilray Brands released FY2026 Q3 earnings on April 1 Pre-Market EST, actual revenue USD 206.73 M (forecast USD 201.3 M), actual EPS USD -0.2399 (forecast USD -0.136)

Tilray Reports Earnings and Plans to Acquire BrewDog

TD Cowen Analyst Assigns Buy Rating to Tilray with a Target Price of $7.00

Tilray Brands to release FY2026 Q3 earnings report on April 1 Pre-Market EST, forecast revenue USD 201.3 M, EPS USD -0.136

Tilray Brands Inc Acquires Brewdog's Key Assets in the US

Tilray Brands Inc. Acquires BrewDog Brewing Australia

Tilray Brands Signs Distribution Agreement with Smartway Pharmaceuticals for UK Pharmaceuticals

Tilray Brands Inc. Launches Tilray Medical Italia to Strengthen Medical Cannabis Business

Tilray Options Volume Increases, Distribution Segment Sets New Revenue Record

Tilray Brands Reports Record Quarterly Net Revenue

Tilray Brands Inc. Reports Q3 Earnings Beat

Tilray Brands released FY2026 Semi-Annual Earnings on January 8 After-Market EST, with actual revenue of USD 427.01 M and EPS of USD -0.4199

Tilray Brands released FY2026 Q2 earnings on January 8 After-Market EST, actual revenue USD 217.51 M (forecast USD 211.15 M), actual EPS USD -0.41 (forecast USD -0.14)

Cannabis Company Q2 2026 Revenue Exceeded Expectations, EPS Loss Narrowed

Tilray Brands Reports Second Quarter Earnings Forecast with EPS Loss

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

TLRY

VEGI

FTAG

CORN

Tilray Brands Inc. (TLRY) shares fell 2.63% to $5.18 on Monday, marking the second consecutive day of losses. The stock is currently 77.67% below its 52-week high of $23.20. The overall market had mixed results, with the Dow Jones up 0.32% and NASDAQ down 0.51%. Trading volume was 3.4 million, below the 50-day average of 4.9 million.

MarketWatch Automated

iShares MSCI Agriculture Producers ETF

VanEck Agribusiness ETF

First Trust Indxx Global Agri

Invesco DB Agriculture FD ETF

Teucrium Corn Fd

Dow Jones Industrial Average

NASDAQ Composite Index

Tilray Brands Inc. Stock Falls Monday, Underperforms Market

TCNNF

CURLF

CRON

GTBIF

MSOS

A new report from the Global Cannabis Network Collective and Whitney Economics highlights pricing compression as a key indicator of cannabis market maturity. It analyzes how expanding supply and evolving regulations impact pricing across emerging markets in Europe and Latin America. The report emphasizes that while initial market prices may be high, sustained downward pressure is common as markets mature. It also discusses the influence of regulatory frameworks and consumer behavior on pricing stability and operator profitability, providing insights for investors and policymakers.

prnewswire

Trulieve Cannabis Corp.

Aurora Cannabis

Curaleaf Holdings, Inc.

Canopy Growth

Cronos

Green Thumb Industries Inc.

AdvisorShares Pure US Cannabis ETF

Amplify Alternative Harvest ETF

07:05 ETNew Global Cannabis Report from GCNC and Whitney Economics Examines How Pricing Compression Reshapes Emerging Markets

Tilray Brands Inc. (TLRY) shares fell 3.27% to $5.32 on Friday, underperforming the market as the NASDAQ Composite dropped 1.54% and the Dow Jones fell 1.07%. This decline ended a two-day winning streak, with the stock still 77.07% below its 52-week high of $23.20 reached on October 9th. Trading volume was 4.3 million, below the 50-day average of 4.9 million.

Tilray Brands Inc. Stock Falls Friday, Underperforms Market

Tilray Brands' stock is experiencing a significant decline, currently trading at its lowest since July last year, down over 76% from its peak in October. The drop accelerated after the Justice Department's announcement to reschedule cannabis, which faces legal challenges. Despite potential benefits from rescheduling, Tilray's beverage division struggles with declining revenue. The stock's technical analysis indicates further downside potential, with the price recently falling below key support levels.

Invezz

Anheuser-Busch InBev NV

Molson Coors Beverage Co-B

Molson Coors Beverage

Tilray Brands stock is in a freefall: key reasons and what next

SBIO

LABU

Tilray Brands Inc. (TLRY) shares fell 1.81% to $5.41 on Tuesday, marking the fourth consecutive day of losses. The stock underperformed in a mixed trading session, with the Dow Jones up 0.11% and NASDAQ down 0.71%. Tilray's stock is currently 76.68% below its 52-week high of $23.20, reached on October 9th. Trading volume was 2.8 million, significantly below the 50-day average of 4.9 million.

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

ALPS Medical Breakthrough

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

Tilray Brands Inc. Stock Falls Tuesday, Underperforms Market

Tilray Brands' stock has plummeted to $5.6, its lowest since August, despite a recent US cannabis reclassification that was expected to benefit the company. Investors sold off shares following the news, as the reclassification was already anticipated. Additionally, concerns over the beverage business's declining revenue and the company's strategy of growth through acquisitions have contributed to the stock's decline. Technical analysis indicates a bearish outlook, with a potential target of $4 unless the stock surpasses the 200-day moving average at $8.65.

Here’s why Tilray Brands stock has crashed after cannabis reclassification

Tilray Brands Inc. (TLRY) shares fell 1.74% to $5.66 on Thursday, underperforming the market amid a broader decline, with the NASDAQ down 0.13% and the Dow Jones down 0.63%. The stock is currently 75.60% below its 52-week high of $23.20, reached on October 9th. Trading volume was 4.0 million, which is below the 50-day average of 4.7 million.

Factset Research

Tilray Brands Inc. Stock Falls Thursday, Underperforms Market

International growth could make up for a lack of U.S. legalization progress

1 Wall Street analyst thinks Tilray will soar nearly 75%. Is it a buy now?

VICE

FTXG

Tilray Brands is a significant player in the $7.4 billion cannabis beverage market, with a strong presence in Canada and the U.S. However, the company faces challenges, including inconsistent revenue growth and net losses. While the cannabis market is projected to grow, potential federal legalization in the U.S. could bring both opportunities and increased competition. Analysts suggest that Tilray may not be a worthwhile investment at this time, recommending investors consider other stocks instead.

nasdaq

AdvisorShares Vice - ETF

First Trust NASDAQ Food & Beverage

Is Tilray the Best Value Play in the $7.4 Billion Cannabis Beverage Market?

Tilray Brands(TLRY.US)